Primary Progressive Multiple Sclerosis: Putting Together the Puzzle.

Area of Science:

• Neuroimmunology
• Neurology

Background:

• Primary progressive multiple sclerosis (PPMS) is a challenging neurological condition with complex risk factors including genetics, age, and Epstein-Barr virus (EBV) infection.
• Pathophysiology involves inflammation-associated axonal loss, glial cell activation (astrocytes, microglia), mitochondrial dysfunction, and iron accumulation.
• Histological studies show inflammatory cell infiltration in gray matter, white matter, and meninges.

Purpose of the Study:

• To summarize recent advances in understanding PPMS risk factors and pathophysiology.
• To review current and emerging treatment strategies for PPMS.
• To introduce a novel conceptual framework for understanding PPMS and future treatments.

Main Methods:

• Review of current scientific literature on PPMS.
• Analysis of histological findings and clinical trial data.
• Synthesis of information on risk factors, disease mechanisms, and therapeutic interventions.

Main Results:

• Ocrelizumab, a B-cell-depleting antibody, demonstrated efficacy in a Phase 3 PPMS trial, challenging previous treatment paradigms.
• Emerging treatments like MD1003 for remyelination enhancement and EBV-directed therapies show future potential.
• New insights into risk factors and pathophysiological pathways are emerging.

Conclusions:

• PPMS pathophysiology is complex, involving multiple interacting factors.
• Targeted therapies, such as ocrelizumab, offer new hope for treating PPMS.
• Future research directions include novel remyelination strategies and EBV-targeted treatments.